A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma

Who May Qualify:• diagnosed by tissue sample (biopsy-confirmed) locally advanced (unresectable) or metastatic melanoma (with the exception of ocular uveal melanoma). Patients who have progressed or relapsed after at least 1st-line systemic standard therapy. - Male or non-pregnant, non-lactating female subjects aged ≥18 years. - You should be able to carry out daily activities with 0 level of ability (ECOG 0)\~1. - Has at least 1 measurable lesion as defined by RECIST 1.1 criteria. - Life expectancy of ≥3 months, in the opinion of the Investigator. - Able to take oral medications and willing to record daily adherence to investigational product. - Adequate hematologic parameters. - Adequate renal and hepatic function - Able to understand and willing to sign a written willing to sign a consent form form. - Consent to provide archived tissue specimen or tissue sample. Who Should NOT Join This Trial:• History of another malignancy. - Known symptomatic brain metastases requiring \>10 mg/day of prednisolone. - Significant cardiovascular disease. - Known active HBV, HCV, AIDS-related illness. - Has received a live vaccine within 30 days. - History of active autoimmune disorders, or ongoing immunosuppressive therapy. - Continuance of toxicities due to prior radiotherapy or chemotherapy agents that do not recover to \< Grade 2. - Receiving concurrent anti-cancer therapy, investigational product, strong inhibitors or inducers of cytochrome P450 3A (CYP3A) . - Prior treatment with other hematopoietic progenitor kinase 1 (HPK1) inhibitors. - Allergy to the ingredients of study drug, or a history of other allergies which were judged by the investigator to be unsuitable for participation in the study. Always talk to your doctor about whether this trial is right for you.